Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

PURPOSE: Resistance to trastuzumab therapy is linked to phosphoinositol 3-kinase (PI3K) pathway activation. One key downstream effector and regulator of this pathway is the mechanistic target of rapamycin (mTOR). In 2011, a phase I/II study evaluated the combination of trastuzumab and everolimus (a...

Descripción completa

Detalles Bibliográficos
Autores principales: de Oliveira Taveira, Mateus, Nabavi, Sheida, Wang, Yuker, Tonellato, Peter, Esteva, Francisco J., Cantley, Lewis C., Wulf, Gerburg M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486569/
https://www.ncbi.nlm.nih.gov/pubmed/28247034
http://dx.doi.org/10.1007/s00432-017-2358-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486569/
https://www.ncbi.nlm.nih.gov/pubmed/28247034
http://dx.doi.org/10.1007/s00432-017-2358-x

Ejemplares similares